Mineralys Therapeutics (MLYS) Insider Trading & Ownership $14.92 -0.63 (-4.05%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Mineralys Therapeutics (NASDAQ:MLYS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage25.56%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$25.60MNumber OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$10.49M Get MLYS Insider Trade Alerts Want to know when executives and insiders are buying or selling Mineralys Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MLYS Insider Buying and Selling by Quarter Mineralys Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/14/2025David Malcom RodmanInsiderSell11,366$15.29$173,786.14 4/14/2025David Malcom RodmanInsiderSell11,366$14.53$165,147.98 4/11/2025Adam Scott LevyCFOSell10,757$12.06$129,729.42 4/11/2025Jon CongletonCEOSell15,319$12.19$186,738.61 4/1/2025David Malcom RodmanInsiderSell55,771$15.76$878,950.96 3/13/2025Ra Capital Management, L.P.DirectorBuy1,296,296$13.50$17,499,996.00 3/13/2025Samsara Biocapital Gp, LlcMajor ShareholderBuy600,000$13.50$8,100,000.00 1/13/2025Adam Scott LevyCFOSell10,757$9.10$97,888.70 1/13/2025Jon CongletonCEOSell18,333$9.06$166,096.98 11/6/2024David Malcom RodmanInsiderSell25,482$15.03$382,994.46 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/11/2024Adam Scott LevyCFOSell10,757$13.57$145,972.49 10/11/2024Jon CongletonCEOSell15,271$13.52$206,463.92 7/24/2024Brian Taylor SlingsbyDirectorSell550,000$13.05$7,177,500.00 7/16/2024David Malcom RodmanInsiderSell525$15.00$7,875.00 7/11/2024Adam Scott LevyCFOSell10,757$13.14$141,346.98 7/11/2024Jon CongletonCEOSell15,746$13.34$210,051.64 6/14/2024Jon CongletonCEOSell16,229$12.52$203,187.08 6/12/2024Jon CongletonCEOSell16,607$12.77$212,071.39 (Data available from 1/1/2013 forward) MLYS Insider Trading Activity - Frequently Asked Questions Who is on Mineralys Therapeutics's Insider Roster? The list of insiders at Mineralys Therapeutics includes Adam Scott Levy, Brian Taylor Slingsby, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, L.P., and Samsara Biocapital Gp, Llc. Learn more on insiders at MLYS. What percentage of Mineralys Therapeutics stock is owned by insiders? 25.56% of Mineralys Therapeutics stock is owned by insiders. Learn more on MLYS's insider holdings. Which Mineralys Therapeutics insiders have been buying company stock? The following insiders have purchased MLYS shares in the last 24 months: Jon Congleton ($105,557.50), Ra Capital Management, L.P. ($17,499,996.00), and Samsara Biocapital Gp, Llc ($15,599,992.50). How much insider buying is happening at Mineralys Therapeutics? Insiders have purchased a total of 2,462,601 MLYS shares in the last 24 months for a total of $33,205,546.00 bought. Which Mineralys Therapeutics insiders have been selling company stock? The following insiders have sold MLYS shares in the last 24 months: Adam Scott Levy ($1,767,723.69), Brian Taylor Slingsby ($7,177,500.00), David Malcom Rodman ($3,622,590.25), and Jon Congleton ($1,184,609.62). How much insider selling is happening at Mineralys Therapeutics? Insiders have sold a total of 1,049,049 Mineralys Therapeutics shares in the last 24 months for a total of $13,752,423.56 sold. Mineralys Therapeutics Key ExecutivesDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Compensation: $69.33kMr. Jon Congleton (Age 61)CEO & Director Compensation: $775.77k2 recent tradesMr. Adam Scott Levy (Age 46)CFO & Secretary Compensation: $655.58k2 recent tradesDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Compensation: $726.95kMs. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical Operations More Insider Trading Tools from MarketBeat Related Companies MRUS Insider Buying RYTM Insider Buying AKRO Insider Buying RNA Insider Buying PTCT Insider Buying CYTK Insider Buying SRPT Insider Buying KRYS Insider Buying ACAD Insider Buying SWTX Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Summer Stocks With Insider Buying and Analyst Support3 Tightly-Held Growth Stocks Set Up for Short SqueezesTankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneDividend Investors Looking for an Edge? 3 Stocks Insiders Bought This page (NASDAQ:MLYS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
